| Item Type | Name |
|
Concept
|
Sulfonamides
|
|
Academic Article
|
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.
|
|
Academic Article
|
Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments.
|
|
Academic Article
|
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
|
|
Academic Article
|
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
|
|
Academic Article
|
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells.
|
|
Academic Article
|
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
|
|
Academic Article
|
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models.
|
|
Academic Article
|
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
|
|
Academic Article
|
Venetoclax-based therapies for acute myeloid leukemia.
|
|
Academic Article
|
How I treat acute myeloid leukemia in the era of new drugs.
|
|
Academic Article
|
Single-agent and combination biologics in acute myeloid leukemia.
|
|
Academic Article
|
Venetoclax in acute myeloid leukemia - current and future directions.
|
|
Academic Article
|
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.
|
|
Academic Article
|
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
|
|
Academic Article
|
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.
|
|
Academic Article
|
Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
|
|
Academic Article
|
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.
|
|
Academic Article
|
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
|
|
Academic Article
|
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
|
|
Academic Article
|
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.
|
|
Academic Article
|
New directions for emerging therapies in acute myeloid leukemia: the next chapter.
|
|
Academic Article
|
Azacitidine and Venetoclax in AML. Reply.
|
|
Academic Article
|
Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax.
|
|
Academic Article
|
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
|
|
Academic Article
|
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.
|
|
Academic Article
|
Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.
|
|
Academic Article
|
Hypomethylating agents and venetoclax in acute myeloid leukemia.
|
|
Academic Article
|
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
|
|
Academic Article
|
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia.
|
|
Academic Article
|
Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia.
|
|
Academic Article
|
Activity of venetoclax-based therapy in chronic myelomonocytic leukemia.
|
|
Academic Article
|
Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs.
|
|
Academic Article
|
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.
|
|
Academic Article
|
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
|
|
Academic Article
|
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
|
|
Academic Article
|
Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
|
|
Academic Article
|
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
|
|
Academic Article
|
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
|
|
Academic Article
|
Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
|
|
Academic Article
|
Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.
|
|
Academic Article
|
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
|
|
Academic Article
|
Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
|
|
Academic Article
|
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia.
|
|
Academic Article
|
Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm.
|
|
Academic Article
|
Measurable Residual Disease Response and Prognosis in Treatment-Na?ve Acute Myeloid Leukemia With Venetoclax and Azacitidine.
|
|
Academic Article
|
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
|
|
Academic Article
|
A venetoclax bench-to-bedside story.
|
|
Academic Article
|
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.
|
|
Academic Article
|
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
|
|
Academic Article
|
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Na?ve Acute Myeloid Leukemia.
|
|
Academic Article
|
Impact of Venetoclax and Azacitidine in Treatment-Na?ve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations.
|
|
Academic Article
|
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study.
|
|
Academic Article
|
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia.
|
|
Academic Article
|
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia.
|
|
Academic Article
|
Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML.
|
|
Academic Article
|
Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia.
|
|
Academic Article
|
Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia.
|
|
Academic Article
|
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.
|
|
Academic Article
|
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
|
|
Academic Article
|
Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study.
|
|
Academic Article
|
Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.
|
|
Academic Article
|
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.
|
|
Academic Article
|
Toward an improved understanding of hypomethylating agent and venetoclax therapies.
|
|
Academic Article
|
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax.
|
|
Academic Article
|
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
|
|
Academic Article
|
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
|
|
Academic Article
|
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
|
|
Academic Article
|
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial.
|